Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2023-07-05 Board/Management Inform…
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Vicore announces CEO recruitment process
Board/Management Information Classification · 98% confidence The document is a press release announcing that the CEO, Carl-Johan Dalsgaard, intends to retire and that a recruitment process has been initiated. This constitutes an announcement of a change in senior management. Based on the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and structured like a regulatory news service announcement, but the core content is management change, making MANG the most specific fit over the general RNS fallback.
2023-07-05 English
Bulletin from the extraordinary general meeting of Vicore Pharma Holding AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled 'Bulletin from the extraordinary general meeting of Vicore Pharma Holding AB (publ)' and details resolutions passed during the EGM, specifically concerning the issuance of new shares. This content directly relates to shareholder voting and meeting outcomes. Although it discusses a capital action (share issue), the primary context is the meeting itself. Since the document reports the *results* of a shareholder vote/meeting, the most appropriate classification is AGM-R (AGM Information), as EGMs often fall under the broader category of general meetings covered by this code, especially when reporting resolutions. Alternatively, it could be considered CAP (Capital/Financing Update) due to the share issuance, but the structure is that of a meeting bulletin. Given the explicit mention of 'extraordinary general meeting' and the reporting of resolutions, AGM-R is the strongest fit among the provided options for meeting outcomes.
2023-07-05 English
Kommuniké från extra bolagsstämma i Vicore Pharma Holding AB (publ)
Share Issue/Capital Change Classification · 99% confidence The document is titled "Kommuniké från extra bolagsstämma i Vicore Pharma Holding AB (publ)" which translates to 'Communiqué from the Extraordinary General Meeting'. It details decisions made at the EGM on July 5, 2023, specifically concerning the issuance of new shares (a capital/financing activity) based on a board decision. Although it involves a shareholder vote outcome (issuance approval), the primary nature of the document is the official announcement/minutes of the Extraordinary General Meeting (AGM/EGM). Since there is no specific code for an EGM communiqué, and it relates directly to the meeting proceedings and decisions, it aligns best with AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. Given the context of a formal meeting communiqué, AGM-R is the most appropriate fit among the provided options, although it is an 'Extra' meeting. The document is short and reports the outcome, not just announcing a future report.
2023-07-05 Swedish
Major Shareholding Notification 2023
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding percentage by a specific holder ('HealthCap VII L.P.') in the issuer ('Vicore Pharma Holding AB'). It explicitly mentions 'Reason for major shareholding notification' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' quantities, including the resulting percentage (18.92939 %). This structure is characteristic of a notification regarding a significant change in ownership, which aligns with the definition of Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-06-30 English
Ökning av antalet aktier och röster i Vicore Pharma
Share Issue/Capital Change Classification · 98% confidence The document is a short announcement dated June 30, 2023, detailing an increase in the number of shares and votes due to directed new share issues (nyemissioner) completed in June 2023, and mentioning future share issues contingent on an Extraordinary General Meeting (EGM) on July 5, 2023. This directly relates to changes in the company's capital structure and share count. This fits the definition of 'Capital/Financing Update' (CAP) or potentially 'Share Issue/Capital Change' (SHA). Since the core content is the announcement of the issuance of new shares and the resulting total share count, SHA is the most precise fit. The document is short and appears to be a regulatory press release announcing the change, rather than a comprehensive financial report.
2023-06-30 Swedish
Increase of number of shares and votes in Vicore Pharma
Share Issue/Capital Change Classification · 99% confidence The document announces an increase in the number of shares and votes for Vicore Pharma Holding AB, detailing the issuance of 29,875,000 shares and the resulting total number of shares and registered share capital as of June 30, 2023. This directly relates to changes in the company's capital structure due to share issuances. This fits the definition of 'Capital/Financing Update' (CAP). Although it involves shares, it is not a report of the company buying back or selling its own shares (POS), but rather the result of a directed issuance/fundraising activity. It is not a general regulatory filing (RNS) because it fits a more specific category (CAP). The document length is relatively short (3831 chars) and it is an announcement of a corporate action, not a comprehensive report.
2023-06-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.